Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.

Pregnancy Humans Female Mice Animals Pregnancy, Unplanned HIV Infections / prevention & control
Contraception Drug delivery HIV Injectable Polymer

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
11 2023
Historique:
received: 31 05 2023
revised: 30 09 2023
accepted: 02 10 2023
medline: 3 11 2023
pubmed: 6 10 2023
entrez: 5 10 2023
Statut: ppublish

Résumé

Only condoms are proven to protect against both HIV and unplanned pregnancy, however, poor user acceptability and lack of partner cooperation impede effectiveness. We developed an injectable ultra-long-acting, biodegradable, and removable in-situ forming implant (ISFI) as multipurpose prevention technology (MPT). MPT ISFIs co-formulated an antiretroviral (dolutegravir (DTG)) or cabotegravir (CAB)), and a hormonal contraceptive (etonogestrel (ENG) or medroxyprogesterone acetate (MPA)). All formulations were well-tolerated in mice with no signs of chronic local or systemic inflammation. Plasma CAB and DTG concentrations were above 4× PA-IC

Identifiants

DOI: 10.1016/j.jconrel.2023.10.006 PMID: 37797892
pubmed: 37797892
pii: S0168-3659(23)00656-9
doi: 10.1016/j.jconrel.2023.10.006
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

606-620

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI150358
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150358
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001109
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

Isabella C Young (IC)

Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Aryani Pallerla (A)

Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Mackenzie L Cottrell (ML)

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Panita Maturavongsadit (P)

Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Alka Prasher (A)

Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Roopali Shrivastava (R)

Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Gabriela De la Cruz (G)

UNC School of Medicine, Pathology and Lab Medicine, Chapel Hill, NC, USA.

Stephanie A Montgomery (SA)

UNC School of Medicine, Pathology and Lab Medicine, Chapel Hill, NC, USA.

Amanda Schauer (A)

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Craig Sykes (C)

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Angela D M Kashuba (ADM)

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

S Rahima Benhabbour (SR)

Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: benhabs@email.unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Long-acting injectable multipurpose prevention...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Long-acting injectable multipurpose prevention...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Long-acting injectable multipurpose prevention...
questionsmedicales.fr › Eucaryotes › Animaux › Long-acting injectable multipurpose prevention...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Grossesse non planifiée › Long-acting injectable multipurpose prevention...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Long-acting injectable multipurpose prevention...